Clinical trials: First Relapse
ACUTE LYMPHOBLASTIC LEUKEMIA
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
This prospective, randomized, multicenter, open-label Phase 2 study is designed to evaluate the superiority of InO monotherapy vs ALLR3 after 1 cycle of induction treatment in paediatric participants (between 1 and <18 years)…
- Trial name
- NCT05748171
- Testing
- Inotuzumab ozogamicin, ALLR3
- Where
- 65 sites in Austria, Belgium and 13 more
- Volunteers
- 100 people
- Sponsor
- Pfizer
Acute Myeloid Leukemia
First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
This study is a First In Human, phase 1, open-label, non-randomized, multi-center, multiple ascending dose escalation study evaluating AFM28 as a monotherapy in subjects with Relapsed/Refractory CD123-positive Acute Myeloid…
- Trial name
- NCT05817058
- Testing
- AFM28
- Where
- 5 sites in France, Spain
- Volunteers
- 30 people
- Sponsor
- Affimed GmbH
Head and Neck Cancer
Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug and giving the drugs in different ways may kill more tumor cells.
- Trial name
- NCT00022217
- Testing
- carboplatin, cisplatin-e therapeutic implant, paclitaxel
- Where
- 4 sites in United States
- Sponsor
- Matrix Pharmaceutical